BioMarin discontinues dosing in certain Voxzogo trials after safety concern [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
Syndrome, SHOX-deficiency and Aggrecan (ACAN)-deficiency after safety events in two investigator-led trials. According to a US Securities and Exchange Commission (SEC) listing, filed on 16 March, several patients suffered slipped capital femoral epiphysis (SCFE) in two ongoing investigator-sponsored trials. This event is characterised by the head of the femur slipping backwards off the growth plate. BioMarin said that SCFE events have not been observed in its other Phase II trials in these same conditions. The company added that no cases have been observed in the more than 5,000 infants and children who have received Voxzogo for achondroplasia in clinical studies or post-marketing surveillance. There have similarly been no observed cases in BioMarin's clinical trials for hypochondroplasia, an indication in which BioMarin is focusing for the drugs next approval. The Phase II CANOPY trials of Voxzogo in children with Noonan syndrome (NCT06668805), as well as those living with id
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks [Yahoo! Finance]Yahoo! Finance
- How The BioMarin (BMRN) Story Is Shifting With Voxzogo Risks And The Amicus Deal [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical (BMRN) had its "outperform" rating reaffirmed by Wolfe Research.MarketBeat
- BioMarin stops mid-stage trials of bone disorder treatment [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents [Yahoo! Finance]Yahoo! Finance
BMRN
Earnings
- 2/23/26 - Beat
BMRN
Sec Filings
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- BMRN's page on the SEC website